Abbott Laboratories (ABT) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1149706,
    "name": "Abbott Laboratories",
    "stock_name": "Abbott Laboratories",
    "full_name": "Abbott Laboratories",
    "name_url": "stocks-analysis/abbott-laboratories",
    "exchange": 207,
    "exchangecode": "NYS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "125.12",
    "chg": -1.59,
    "chgp": "-1.25%",
    "dir": -1,
    "prev_price": "126.71",
    "mcapval": "258,487.47",
    "mcap": "Large Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2325,
    "indexname": "S&P 500",
    "isin": "US0028241000",
    "curr_date": "Dec 18",
    "curr_time": "",
    "bse_nse_vol": "11.78 M",
    "exc_status": "Active",
    "traded_date": "Dec 18, 2025",
    "traded_date_str": "2025 12 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/abbott-laboratories-1149706-207&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Abbott Laboratories overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-overvalued-or-undervalued-3728312",
        "imagepath": "",
        "date": "2025-11-25 11:13:52",
        "description": "As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price.\n\nIn comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods...."
      },
      {
        "title": "Is Abbott Laboratories overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-overvalued-or-undervalued-3723306",
        "imagepath": "",
        "date": "2025-11-23 11:09:25",
        "description": "As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price.\n\nIn comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance...."
      },
      {
        "title": "Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/abbott-laboratories-technical-trend-shifts-from-bullish-to-mildly-bullish-amid-stock-price-decline-3619721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AbbottLaborator_technicaldot_3619721.png",
        "date": "2025-10-14 15:37:50",
        "description": "Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.38, reflecting a year of notable highs and lows. Technical indicators present mixed signals, while Abbott's year-to-date performance has outpaced the S&P 500, though longer-term returns remain less competitive."
      },
      {
        "title": "Is Abbott Laboratories technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-technically-bullish-or-bearish-3612750",
        "imagepath": "",
        "date": "2025-10-12 11:22:10",
        "description": "As of 10 October 2025, the technical trend for Abbott Laboratories has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish. The daily moving averages indicate a bullish stance. The Bollinger Bands show a sideways trend on the weekly chart and mildly bullish on the monthly chart. KST is bullish on both weekly and monthly time frames, but the OBV is mildly bearish weekly with no trend monthly. \n\nIn terms of performance, Abbott has outperformed the S&P 500 over the past month with a return of 2.48% compared to the S&P 500's 0.31%, and it has also shown strong year-to-date performance at 17.20% versus the S&P 500's 11.41%. However, over longer periods, Abbott's returns have lagged significantly behind the S&P 500. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators...."
      },
      {
        "title": "Is Abbott Laboratories technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-technically-bullish-or-bearish-3544815",
        "imagepath": "",
        "date": "2025-09-20 18:56:42",
        "description": "As of 12 September 2025, the technical trend for Abbott Laboratories has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, while the RSI is bullish on the weekly but shows no signal on the monthly. Bollinger Bands are also bullish in both time frames. However, the KST is mildly bearish on the weekly, and the Dow Theory indicates no trend on the weekly and mildly bearish on the monthly, which adds some caution. The daily moving averages are bullish.\n\nIn terms of performance, Abbott Laboratories has outperformed the S&P 500 over the past week (1.45% vs. 1.05%) and over the past month (3.30% vs. 2.33%), but it has lagged behind the S&P 500 in the longer-term returns, particularly over 3 years (29.39% vs. 70.41%) and 5 years (25.93% vs. 96.61%)...."
      },
      {
        "title": "Is Abbott Laboratories overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-abbott-laboratories-overvalued-or-undervalued-3541542",
        "imagepath": "",
        "date": "2025-09-20 17:28:41",
        "description": "As of 17 July 2025, Abbott Laboratories has moved from a very attractive to a fair valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, which suggests strong growth potential relative to its price. In comparison, Thermo Fisher Scientific has a P/E of 30.06, indicating that Abbott is more attractively priced within its peer group, while Medtronic shows a P/E of 21.47, further supporting the notion of Abbott's fair valuation.\n\nDespite the recent stock performance, where Abbott returned 18.97% year-to-date compared to the S&P 500's 12.22%, the longer-term returns reveal a lag, with a 3-year return of 29.39% versus the S&P's 70.41%. This indicates that while Abbott has performed well recently, its longer-term growth has not kept pace with the broader market, reinforcing the fair valuation a..."
      }
    ],
    "total": 12,
    "sid": "1149706",
    "stock_news_url": "https://www.marketsmojo.com/news/abbott-laboratories-1149706"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Abbott Laboratories overvalued or undervalued?

2025-11-25 11:13:52

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating strong growth potential relative to its price. In comparison to its peers, Abbott Laboratories has a more favorable P/E ratio of 18.36 compared to Thermo Fisher Scientific's 30.06 and Medtronic's 21.47, suggesting that it is priced more competitively within the industry. Despite a recent decline in stock price, Abbott has outperformed the S&P 500 year-to-date with a return of 12.45% compared to the index's 12.26%, although it has lagged significantly over the longer three and five-year periods....

Is Abbott Laboratories overvalued or undervalued?

2025-11-23 11:09:25

As of 21 November 2025, the valuation grade for Abbott Laboratories has moved from very attractive to attractive. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, indicating a strong growth potential relative to its price. In comparison to peers, Abbott's P/E ratio of 18.36 is significantly lower than that of Thermo Fisher Scientific at 30.06 and Stryker Corp. at 33.17, suggesting it is more attractively priced in the market. Additionally, while Abbott's one-year return of 9.25% lags behind the S&P 500's 11.00%, its year-to-date return of 13.26% exceeds the S&P's 12.26%, reinforcing a positive outlook despite the longer-term underperformance....

Abbott Laboratories Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-14 15:37:50

Abbott Laboratories has recently revised its evaluation amid changing market conditions. The stock is priced at $131.38, reflecting a year of notable highs and lows. Technical indicators present mixed signals, while Abbott's year-to-date performance has outpaced the S&P 500, though longer-term returns remain less competitive.

Is Abbott Laboratories technically bullish or bearish?

2025-10-12 11:22:10

As of 10 October 2025, the technical trend for Abbott Laboratories has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish. The daily moving averages indicate a bullish stance. The Bollinger Bands show a sideways trend on the weekly chart and mildly bullish on the monthly chart. KST is bullish on both weekly and monthly time frames, but the OBV is mildly bearish weekly with no trend monthly. In terms of performance, Abbott has outperformed the S&P 500 over the past month with a return of 2.48% compared to the S&P 500's 0.31%, and it has also shown strong year-to-date performance at 17.20% versus the S&P 500's 11.41%. However, over longer periods, Abbott's returns have lagged significantly behind the S&P 500. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators....

Is Abbott Laboratories technically bullish or bearish?

2025-09-20 18:56:42

As of 12 September 2025, the technical trend for Abbott Laboratories has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, while the RSI is bullish on the weekly but shows no signal on the monthly. Bollinger Bands are also bullish in both time frames. However, the KST is mildly bearish on the weekly, and the Dow Theory indicates no trend on the weekly and mildly bearish on the monthly, which adds some caution. The daily moving averages are bullish. In terms of performance, Abbott Laboratories has outperformed the S&P 500 over the past week (1.45% vs. 1.05%) and over the past month (3.30% vs. 2.33%), but it has lagged behind the S&P 500 in the longer-term returns, particularly over 3 years (29.39% vs. 70.41%) and 5 years (25.93% vs. 96.61%)....

Is Abbott Laboratories overvalued or undervalued?

2025-09-20 17:28:41

As of 17 July 2025, Abbott Laboratories has moved from a very attractive to a fair valuation grade. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 19, an EV to EBITDA of 25.84, and a PEG ratio of 0.14, which suggests strong growth potential relative to its price. In comparison, Thermo Fisher Scientific has a P/E of 30.06, indicating that Abbott is more attractively priced within its peer group, while Medtronic shows a P/E of 21.47, further supporting the notion of Abbott's fair valuation. Despite the recent stock performance, where Abbott returned 18.97% year-to-date compared to the S&P 500's 12.22%, the longer-term returns reveal a lag, with a 3-year return of 29.39% versus the S&P's 70.41%. This indicates that while Abbott has performed well recently, its longer-term growth has not kept pace with the broader market, reinforcing the fair valuation a...

View All News